@article{06c2c26ab4e14bc8a6e90d0a5570983c,
title = "APOE modifies the association between Aβ load and cognition in cognitively normal older adults",
abstract = "Objective: To determine the relationship between β-amyloid (Aβ) load as measured by [11C]- Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults. Methods: We studied 408 cognitively normal older adults who participated in the population-based Mayo Clinic Study of Aging (MCSA) from January 2009 through March 2011. The participants underwent PiB PET and neuropsychometric testing within 6 months. The association between PiB retention and cognitive function was measured by partial correlation and an interaction with APOE status was tested using linear regression after adjusting for age, sex, and education. Results: Higher PiB retention was associated with cognitive performance (Spearman partial r =-0.18; p < 0.01), specifically the memory, language, attention/executive, and visual-spatial processing domains in the whole group of participants. The association between PiB retention and cognition was modified by the APOE status on linear regression analysis even after controlling for the differences in the distribution of PiB values among APOE ε4 carriers and noncarriers (p =0.02). Cognitive performance was associated with the Aβ deposition in the frontal, temporal, and parietal lobe association cortices in APOE ε4 carriers on SPM analysis (p < 0.001). Conclusion: There is a modest association between PiB retention and cognitive function in cognitively normal older adults and this relationship between Aβ load and cognitive function is modified by APOE status. Whereas Aβ load is associated with greater cognitive impairment in APOE ε4 carriers, the cognitive function in APOE ε4 noncarriers is influenced less by the Aβ load, suggesting that APOE isoforms modulate the harmful effects of Aβ on cognitive function.",
author = "K. Kantarci and V. Lowe and Przybelski, {S. A.} and Weigand, {S. D.} and Senjem, {M. L.} and Ivnik, {R. J.} and Preboske, {G. M.} and R. Roberts and Geda, {Y. E.} and Boeve, {B. F.} and Knopman, {D. S.} and Petersen, {R. C.} and Jack, {C. R.}",
note = "Funding Information: Study funding: NIH (K23 AG030935, R01 AG11378, U01 AG 06786) . Support for several investigators was provided by the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation and the NIH Construction Grant ( NIH C06 RR018898 ). Funding Information: Dr. Kantarci receives research support from the NIH. Dr. Lowe serves on scientific advisory boards for Bayer Schering Pharma and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, the NIH (NIA, NCI), the MN Partnership for Biotechnology and Medical Genomics, and the Leukemia & Lymphoma Society. S. Przybelski and S. Weigand report no disclosures. M.L. Senjem has received research support from Pfizer Inc. Dr. Ivnik serves on the editorial boards of The Clinical Neuropsychologist and Aging, Neuropsychology, and Cognition; receives publishing royalties for Clinical Interpretation of the WAIS-III and WMS-III (Academic Press, 2003); and receives research support from the NIH/NIA. G. Preboske reports no disclosures. Dr. Roberts serves as an Associate Editor for the Journal of Alzheimer's Disease and receives research support from Abbott and the NIH. Dr. Geda receives research support from the NIH and the RWJ Foundation. Dr. Boeve receives publishing royalties for The Behavioral Neurology of Dementia (Cambridge University Press, 2009) and receives research support from Cephalon, Inc., Allon Therapeutics, Inc., the NIH/NIA, the Alzheimer's Association, and the Mangurian Foundation. Dr. Knopman serves as Deputy Editor for Neurology{\textregistered}; serves on a data safety monitoring board for Eli Lilly and Company; has served as a consultant for Elan/Janssen AI; is an investigator in clinical trials sponsored by Elan/Janssen AI, Baxter International Inc., and Forest Laboratories, Inc.; and receives research support from the NIH. Dr. Petersen serves on scientific advisory boards for the Alzheimer's Association, the National Advisory Council on Aging (NIA), Elan/Janssen AI, Pfizer Inc (Wyeth), and GE Healthcare; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); serves as a consultant for Elan/Janssen AI and GE Healthcare; and receives research support from the NIH/NIA. Dr. Jack serves on scientific advisory boards for Elan/Janssen AI, Eli Lilly & Company, GE Healthcare, and Eisai Inc.; receives research support from Baxter International Inc., Allon Therapeutics, Inc., Pfizer Inc, the NIH/NIA, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and holds stock/stock options in Johnson & Johnson.",
year = "2012",
month = jan,
day = "24",
doi = "10.1212/WNL.0b013e31824365ab",
language = "English (US)",
volume = "78",
pages = "232--240",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}